Click here to review our online proxy materials.
	Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals
	Sepracor Inc. Presented Leadership Award for Contributions to Growth of Community
	Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
	Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada